LY 545694

Drug Profile

LY 545694

Latest Information Update: 08 Sep 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Eli Lilly
  • Class
  • Mechanism of Action Kainic acid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Musculoskeletal pain; Neuropathic pain

Most Recent Events

  • 08 Sep 2015 No recent reports on development identified - Phase-II for Musculoskeletal pain in USA (PO)
  • 08 Sep 2015 No recent reports on development identified - Phase-II for Neuropathic pain in Puerto Rico, Mexico and USA (PO)
  • 30 Jun 2010 Eli Lilly completes phase II trials in Neuropathic pain and Musculoskeletal pain
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top